Interleukin-6 is elevated in plasma in multiple sclerosis

K Frei1, S Fredrikson, A Fontana

  • 1Section of Clinical Immunology, University Hospital, Zürich, Switzerland.

Insights

Interleukin-6 (IL-6) levels were higher in the plasma of multiple sclerosis (MS) patients compared to other conditions. This suggests a potential systemic B cell response in MS, though its significance remains unclear.

Area of Science:

  • Neuroimmunology
  • Cytokine Research

Background:

  • Interleukin-6 (IL-6) is a cytokine crucial for B cell immunoglobulin production.
  • Elevated IL-6 levels are implicated in various inflammatory and neurological conditions.

Purpose of the Study:

  • To measure and compare IL-6 levels in cerebrospinal fluid (CSF) and plasma of patients with multiple sclerosis (MS), acute meningo-encephalitis (AM), and tension headache (TH).
  • To investigate the relationship between IL-6 levels and disease activity in MS.
  • To explore the potential role of IL-6 in the pathophysiology of MS.

Main Methods:

  • Quantification of IL-6 concentrations in both CSF and plasma samples.
  • Comparative analysis of IL-6 levels across patient groups (MS, AM, TH).
  • Longitudinal sampling in MS patients to assess disease activity correlation.

Main Results:

  • MS patients exhibited significantly higher plasma IL-6 levels compared to AM and TH patients.
  • In MS, plasma IL-6 was approximately 17 times higher than CSF IL-6.
  • In AM, CSF IL-6 was 20-fold higher than plasma IL-6 during the acute phase, decreasing with recovery.
  • No correlation was found between IL-6 levels (plasma or CSF) and MS disease activity.

Conclusions:

  • Elevated plasma IL-6 in MS patients supports the hypothesis of a systemic B cell response.
  • The functional significance of increased IL-6 in MS plasma requires further investigation.
  • Distinct IL-6 distribution patterns were observed between MS and AM, highlighting condition-specific cytokine involvement.